<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024435</url>
  </required_header>
  <id_info>
    <org_study_id>415-E/2532/7-2019</org_study_id>
    <nct_id>NCT05024435</nct_id>
  </id_info>
  <brief_title>Evaluation of Semi-rigid and Flexible Catheters for Less Invasive Surfactant Administration in Preterm Infants</brief_title>
  <official_title>Evaluation of Semi-rigid and Flexible Catheters for Less Invasive Surfactant Administration in Preterm Infants With Respiratory Distress Syndrome - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salzburger Landeskliniken</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salzburger Landeskliniken</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this study is to determine the differences between two surfactant&#xD;
      administration catheters in preterm infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single-center, open-label, randomized-controlled trial, preterm infants requiring&#xD;
      surfactant administration after birth, using a standardized minimal invasive protocol, were&#xD;
      randomised to two different modes of endotracheal catheterization: Flexible Ch-4 feeding tube&#xD;
      inserted using Magill forceps (group 1) and semi-rigid catheter (group 2). Primary outcome&#xD;
      was duration of laryngoscopy. Secondary outcomes were complication rate and vital parameters&#xD;
      during laryngoscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful intratracheal tube Placement</measure>
    <time_frame>Birth to 24 hours after birth</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Neonatology</condition>
  <condition>Perinatal Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Nasogastric Tube</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisacath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surfactant Administration</intervention_name>
    <description>Laryngoscopy, intratracheal catheter placement and surfactant administration</description>
    <arm_group_label>Lisacath</arm_group_label>
    <arm_group_label>Nasogastric Tube</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preterm infants born less than 37 weeks of gestation&#xD;
&#xD;
          -  Treating physician in charge of admission decides to administer intratracheal&#xD;
             surfactant via standardized institution- LISA protocol (regardless of this study) (see&#xD;
             Supplement file 1)&#xD;
&#xD;
          -  Written informed consent signed by caregivers or legal representative to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate in study or not providing written informed consent by&#xD;
             caregivers/parents&#xD;
&#xD;
          -  Treating physician decides to use different route of surfactant administration or does&#xD;
             not adhere to LISA protocol.&#xD;
&#xD;
          -  Rupture of membranes (ROM) at less than 22 weeks of gestation or more than 6 weeks&#xD;
             before birth&#xD;
&#xD;
          -  Estimated birth weight &lt; 3rd percentile using 2013 Fenton growth trajectories&#xD;
&#xD;
          -  Twins with feto-fetal transfusion syndrome (FFTS) and FFTS being the cause of&#xD;
             premature delivery&#xD;
&#xD;
          -  Contraindications listed in the LISAcathÂ® or Nasogastric Tube manual&#xD;
             (esophageal/pharyngeal varices or other vascular lesions, esophageal/pharyngeal tumor,&#xD;
             nasal fracture, skull fracture, known allergy to material)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Wald, MD, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paracelsus Medical Private University Salzburg, University Clinic of Pediatrics and Adolescent Medicine Division of Neonatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Salzburger Landeskliniken</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Salzburger Landeskliniken</investigator_affiliation>
    <investigator_full_name>Lorenz Auer-Hackenberg</investigator_full_name>
    <investigator_title>Medical Doctor, University Hospital Salzburg, Department of Pediatrics and Adolescent Medicine, Physician Division of Neonatology</investigator_title>
  </responsible_party>
  <keyword>Less Invasive Surfactant Administration</keyword>
  <keyword>Minimal Invasive Surfactant Treatment</keyword>
  <keyword>Preterm Infant</keyword>
  <keyword>Respiratory Distress Syndrome</keyword>
  <keyword>Surfactant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

